I did watch the
Mary video (the transcript is on
Project Camelot) - wow, lots of night truck movement according to this video, picking up loads of refrigerated cargo, either "antigen or antibody," from silos in Albany, into which the trucks are lowered for loading. The drivers get cash via Bank of America code; freight delivery is apparently financed by Homeland Security.
......................................
H5N1 is avian flu
H1N1 is a combo swine, avian, human. It shares characteristics with spanish flu (1918-20), which Deagle said was a strain made worse by contaminated vaccines -
toxic serum story
Gilead Sciences - NYSE:GILD
http://www.gilead.com/corporate_history
http://investors.gilead.com/phoenix....rol-stockquote
........................................
Don't fear the swine flu . . . trade it
Posted Apr 27th 2009 1:00PM by Melly Alazraki
Filed under: Walgreen Co (WAG), Novartis AG ADS (NVS), Baxter Intl (BAX), CVS Corp (CVS), Hormel Foods (HRL), Tyson Foods'A' (TSN), Smithfield Foods (SFD), Gilead Sciences (GILD), Agriculture
Flu vaccine makers could make an even better bet. At least 20 companies make flu vaccines including Sanofi Pasteur, the vaccine division of Sanofi Aventis Group (NYSE: SNY), Australia's CSL Ltd, London-based GlaxoSmithKline Plc (NYSE: GSK), Novartis AG (NYSE: NVS), Baxter (NYSE: BAX), nasal spray maker MedImmune, acquired by AstraZeneca Plc. (NYSE: AZN) and Swiss based Roche (Other OTC: RHHBY) to name a few.
The main products that currently seem to work against this strain of flu are GSK's Relenza and Roche's Tamiflu, which was originally invented by Gilead Sciences Inc. (NASDAQ: GILD) and gets royalties from its sales. There are concerns, however, that Tamiflu -- taken orally in the form of a tablet -- might be less effective than Relenza, which is inhaled.
Currently, it takes months to make a flu vaccine and it could take years for drug makers to meet global demand. It's no surprise then that stocks of vaccine makers shot up globaly and in the U.S., especially those with licenses to make the aformentioend two drugs.
GSK was the highest gainer.
....................................
About ALDA Pharmaceuticals Corp.
ALDA is focused on the development of infection-control therapeutics derived from its patented T36(R) technology. T36(R) has been proven to be effective against the H1N1 and H3N2 strains of swine flu and against SARS-like viruses. The company trades on the TSX Venture Exchange under the symbol "APH", and is quoted on the OTCBB under the symbol "APCSF".
http://www.tradingmarkets.com/.site/...0News/2293151/